An attempt to visualize baboon brain nicotinic receptors with n-[11c]abt-418 and n-[11c]methyl-cytisine

Nuclear Medicine Communications

Volumn 18, Issue 2, 1997, Pages 164-168

  Valette, H ^a   Bottlaender, M ^a   Dolle F ^a   Dolci, L ^a   Syrota, A ^a   Crouzel, C ^a  

^a DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; CARBON 11; CAULOPHYLLINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BRAIN; CHOLINERGIC SYSTEM; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY;

EID: 0031002184     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199702000-00012     Document Type: Article

References (24)

1. Giacobini E. Cholinergic receptors in human brain: Effect of aging and Alzheimer disease. J Neurosci Res 1990; 27: 548-560.
2. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle PR, Price JT, Kellar KJ. Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res 1986; 371: 146-151.
3. Rinne JO, Myllykyä T, Lönnberg P, Majaräki P. A postmortem study of brain nicotinic receptors in Parkinson’s and Alzheimer’s disease. Brain Res 1991; 547: 167-170.
4. Mazière M, Berger G, Masse R, Plummer R, Comar D. The 'in vivo' distribution of carbon 11 labelled (-)nicotine in animals: A method suitable for use in man. In: Remond A, Izard C, eds. Electrophysiological effects of nicotine. Amsterdam: Elvesier, 1979: 31-47.
5. Nordberg A, Hartvig P, Lundquist H, Antoni G, Ulin J, Langström B. Uptake and regional distribution of (±)-R and (-)-SN-(methyl[nC])-nicotine in the brains of rhesus monkeys: An attempt to study nicotinic receptors in vivo. J Neural Transm (P-D Sect) 1989; 1: 195-205.
6. Halldin C, Nagren K, Swahn C, Langström B, Nybäck H. (S)-and (R)-[nC]nicotine and the metabolite (R/S)-[nC]co-tinine: Preparation, metabolite studies and in vivo distribution in the human brain using PET. Nucl Med Biol 1992; 19: 871-880.
7. Nordberg A, Hartvig P, Lilja A et al. Decreased uptake and binding of P'CJnicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm (P-D Sect) 1990; 2: 215-224.
8. Nybäck H, Halldin C, Ahlin A, Curvall M, Eriksson L. PET studies of the uptake of (S)-and (R)-[nC]nicotine in the human brain: Difficulties in vizualizing specific receptor binding in vivo. Psychopharmacology 1994; 115: 31-36.
9. Mazière M, Delforge J. PET imaging of [nC]nicotine: Historical aspects. In: Domino EF, ed. Brain imaging of nicotine and tobacco smoking. Ann Arbor, MI: NPP Books, 1995: 13-28.
10. Wada E, Wada K, Boulter J et al. Distribution of alpha-2, alpha-3, alpha-4 and beta-2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat. J Comp Neurol 1989; 284: 314-355.
11. Badio B, Daly JW. Epibatidine, a potent analgesic and nicotinic agonist. Mol Pharmacol 1994; 45: 563-569.
12. Hall M, Zerbe L, Leonard S, Freedman R. Characterization of [3H]cytisine binding to human brain preparations. Brain Res 1993; 600: 127-133.
13. Anderson DJ, Williams M, Pauly JR et al Characterisation of [3H]ABT-418: A novel cholinergic channel ligand. J Pharmacol Exp Ther 1995; 273: 1434-1441.
14. Barlow RB, McLeod LJ. Some studies on cytisine and its methylated derivatives. Br J Pharmacal 1969; 35: 161-174.
15. Schmeller T, Sauerwein M, Sporer F, Wink M, Muller W. Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors. J Nat Prod 1994; 57: 1316-1319.
16. Decker MW, Brioni JD, Bannon AW, Arneric SP. Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behaviour and implication for CNS therapeutics. Life Sci 1995; 56: 545-570.
17. Garvey DS, Wasicak JT, Decker MW et al. Novel isoxazoles which interact with brain cholinergic channel have intrinsic cognitive enhancing and anxiolytic activities. J Med Chem 1994; 37: 1055-1059.
18. Dolle F, Dolci L, Valette H et al. Synthesis and [nC] labelling of two selective high affinity nicotinic cholinergic agonists for the evaluation as radioligands for PET studies. J Label Compounds Radiopharm 1996; 32: 1099-1111.
19. Riche D, Hantraye P, Guibert B et al. Anatomical atlas of the baboon’s brain in the orbito-meatal plane used in experimental positron emission tomography. Brain Res Bull 1988, 20: 283-301.
20. Decker MW, Brioni JD, Sullivan JP et al. (S)-3-methyl-5(l-methyl-2-pyrrolidinyl)Isoxazole (ABT418): A novel cholinergic ligand with cognition-enhancing and anxyolitic activities: II. In vivo characterization. J Pharmacol Exp Ther 1994; 270: 319-328.
21. Broussolle EP, Wong DF, Fanelli RJ, London ED. In vivo specific binding of [3H]nicotine in the mouse brain. Life Sci 1989; 44: 1123-1132.
22. Rodrigues AD, Ferrero JL, Amann MT et al. The in vitro metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans. Drug Metab Disp 1994; 22: 788-798.
23. Brioni JD, Kim DJ, Brodie MS, Decker MW, Arneric SP. ABT-418: Discriminative stimulus properties and effect on ventral tegmental cell activity. Psychopharmacology-Berl 1995; 119: 368-375.
24. Flesher JE, Scheffel U, London ED, Frost JJ. In vivo labeling of nicotinic cholinergic receptors in brain with [3H] cytisine. Life Sci 1994; 54: 1883-1890.